Zidovudine, also known as AZT, is an antiretroviral medication used in the treatment of HIV/AIDS. Information regarding specific coupons or discount programs for Zidovudine is not readily available through general searches. Pharmaceutical companies sometimes offer patient assistance programs or savings cards for their medications, but these can vary.
How can I find potential cost savings for Zidovudine?
Individuals seeking to reduce the cost of Zidovudine may explore several avenues. Prescription discount cards and online pharmacies sometimes offer lower prices. Additionally, many pharmaceutical manufacturers have patient assistance programs that provide free or low-cost medication to eligible individuals who meet certain income and insurance requirements. Checking with the specific manufacturer of the Zidovudine being prescribed is a recommended first step.
What are the typical uses and administration of Zidovudine?
Zidovudine is part of combination therapy for HIV infection, helping to prevent the virus from multiplying. It is also used to prevent the transmission of HIV from a pregnant person to their child. The medication is typically taken orally in capsule or syrup form. [1]
When did Zidovudine become available and what is its patent status?
Zidovudine was the first antiretroviral drug approved by the U.S. Food and Drug Administration (FDA) in 1987 for the treatment of HIV/AIDS. [2] As Zidovudine has been available for many decades, its original patents have long since expired. This means that generic versions of Zidovudine are available, which generally leads to lower prices compared to brand-name medications.
Where can I learn more about HIV/AIDS treatment and medications?
For comprehensive information about HIV/AIDS treatment, including antiretroviral therapies like Zidovudine, resources such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) offer extensive patient and professional information. Websites like DrugPatentWatch.com provide data on drug patents and exclusivity periods, which can be relevant for understanding the market availability of medications and potential generic entry. [3]
*
**Sources
1. https://www.ncbi.nlm.nih.gov/books/NBK560670/
2. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cderm/drug-approvals-and-databases
3. https://drugpatentwatch.com/